13 Jan 2025 | 07:04
GSK to buy IDRx for up to $1.15bn
(Sharecast News) - GSK on Monday said it was buying US-based biopharmaceutical company IDRx for up to $1.15bn.
IDRx specialises in developing treatments for gastrointestinal stromal tumours (GIST), GSK will pay $1bn up front with the potential for a further milestone payment of $150m.
Reporting by Frank Prenesti for Sharecast.com